About CYTOCOM INC
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology drug development. The Company�s lead drug candidate CBLB502 is developed for dual indications under the United States Food & Drug Administration's (FDA's) Animal Efficacy Rule, commonly referred to as the Animal Rule, as a radiation countermeasure, and under the FDA's traditional drug approval pathway as an anti-cancer agent and an oncology supportive care therapy. As of December 31, 2011, the Company had nine product candidates in its pipeline that are developed directly by the Company and its majority owned subsidiaries. The products include CBLB502, CBLB502, CBLB502, CBLB612, CBLC102, CBLC137, Revercom, Mobilan, Arkil, Antimycon, and Xenomycins. As of December 31, 2011, the Company had an approximately 75.8% ownership interest in Incuron, LLC (Incuron).As of December 31, 2011, the Company had an ownership stake of approximately 54.6% in Panacela Labs, Inc. (Panacela).